Please login to the form below

Not currently logged in
Email:
Password:

Asthma UK

This page shows the latest Asthma UK news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

News from pharma, biotech and healthcare. Limited NICE approval for AZ’s asthma drug Fasenra. ... However, the UK's cost-effectiveness watchdog says the drug should only be used in limited circumstances for eosinophilic asthma, when usual therapies

Latest news

  • Six new national standards are launched across UK Six new national standards are launched across UK

    Six new national standards are launched across UK. Will help to improve public involvement in research says ABPI’s Mike Thompson. ... The standards will be launched across ten pilot sites in the UK including Asthma UK Centre for Applied Research, the

  • NICE backs Teva's Cinqaero for severe asthma NICE backs Teva's Cinqaero for severe asthma

    Teva's interleukin-5 (IL-5) inhibitor should be made available to patients under the NHS as an add-on therapy for patients with for severe eosinophilic asthma, says the ... Kay Boycott, chief executive of medical charity Asthma UK, welcomed the decision.

  • NICE recognises Smartinhaler as best practice for asthma care NICE recognises Smartinhaler as best practice for asthma care

    According to Asthma UK's Annual Asthma Survey 2016 report, emergency hospital admission is 23 times more expensive than an asthma review, with the annual cost of asthma care in the ... It is shocking that [according to Asthma UK's report] 82% of UK

  • NICE changes stance on GSK's asthma drug Nucala NICE changes stance on GSK's asthma drug Nucala

    Patients in the UK with severe asthma are on course to be able to receive treatment with GlaxoSmithKline's recently approved Nucala drug. ... There are thought to be around 100, 000 people in the UK who have uncontrolled asthma.

  • AstraZeneca to explore link between epigenetics and respiratory diseases AstraZeneca to explore link between epigenetics and respiratory diseases

    AstraZeneca to explore link between epigenetics and respiratory diseases. Joins forces with Asthma UK, the British Lung Foundation and MRC Technology. ... Teaming up with Asthma UK, the British Lung Foundation and independent medical research charity MRC

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics